Adrenal Androgens Regulation and Adrenopause

Total Page:16

File Type:pdf, Size:1020Kb

Adrenal Androgens Regulation and Adrenopause ENDOCRINE REGULATIONS, Vol. 35, 95100, 2001 95 ADRENAL ANDROGENS REGULATION AND ADRENOPAUSE SALVATORE ALESCI 1, CHRISTIAN A. KOCH 1, STEFAN R. BORNSTEIN1, KAREL PACAK1,2 1Pediatric & Reproductive Endocrinology Branch , National Institute of Child Health and Human Development, National Institutes of Health , Bethesda , MD ( USA ); 2Institute of Endocrinology, Prague, Czech Republic E-mail : [email protected] Adrenal androgens (AA) are mainly produced by the human adrenal cortex. ACTH is the major regulator of their secretion. However, other factors, such as gonadal sex steroids, insulin, growth hormone, prolactin, hypothalamic peptides and growth factors have been involved in AA regula- tion. More recently, it has become well accepted that, besides systemic factors, AA secretion is under the control of the sympathoadrenal system and immunoadrenal system. Here we review the extraadrenal and intraadrenal mechanisms of AA regulation and how they may relate to endo- crinoimmunosenescence. Key words : DHEA Adrenal androgens Adrenopause Aging ACTH Minireview Human adrenals produce large amounts of andro- that they may have both androgenic and estrogenic gens, especially dehydroepiandrosterone (DHEA) effect. ADION and T are responsible for 85-90% of and dehydroepiandrosterone sulfate (DHEAS), the total androgenic activity of the adrenal gland, which are the most abundant circulating hormones while DHEA and ADIOL account for the remaining in the human body (ADAMS 1985). Adrenal andro- 10%, being their androgen action mainly dependent gens (AA) are mainly synthesized in the inner zona on conversion to T and 5α-dihydrotestosterone in reticularis (ZR) of the adrenal cortex from the pre- peripheral tissues. ADION is the most important pre- cursor pregnenolone, derived from side-chain cleav- cursor of estrone, the major circulating estrogen in age of cholesterol by cytochrome P450scc enzyme postmenopausal women, while ADIOL can act as (CYPscc). Cytochrome P450-17α (CYP17), a 17α- a classic estrogen both in vitro and in vivo (ADAMS hydroxylase with 17,20-lyase activity converts the 1985). C-21 steroid pregnenolone to the C-19 steroid DHEA, AA production follows a characteristic age-relat- while a hydroxysteroid sulfotransferase (DHEAST) ed pattern. The human fetal adrenal gland undergoes converts DHEA to DHEAS. Alternatively, the ∆5 extensive growth in utero. At the end of gestation, it androgen DHEA can be converted to the ∆4 andro- weighs approximately the same as the adult adrenal gen androstenedione (ADION) by the microsomal because of the presence of a large fetal zone. non-P450 enzyme 3β-hydroxysteroid dehydrogena- A dramatic involution of this zone occurs by un- se (3βHSD) or to androstenediol (ADIOL) by the known mechanism in the first month after birth and 17β-hydroxysteroid oxidoreductase (17βHSOX), continues during the first years of life, being paral- which can also convert ADION to testosterone (T) leled by a sharp decrease in DHEAS, which was the (PARKER 1991). predominant circulating steroid at birth, while corti- The exact biological function of AA is still sol levels remain relatively constant (DE PERETTI and a matter of discussion. However, it is well known FOREST 1978). During the peripubertal period, the 96 DHEA AND ADRENOPAUSE Table 1 Gonadal androgens, for example, have been shown Physiological and pathological states characterized by to inhibit 11β and 21α hydroxylases a divergence of cortisol and (FUJIEDA et al. 1982), while estrogens have been adrenal androgen secretion. reported to stimulate DHEA and DHEAS in vitro PHYSIOLOGICAL. PATHOLOGICAL (GELL et al. 1998) and in vivo (SOBRINHO et al. 1971). Fetal stage Idiopathic hirsutism In addition, DHEAS levels are higher in males vs Obesity, fasting and anorexia nervosa females and sex hormone therapy may reverse this Acute stress from illness or trauma difference (POLDERMAN et al. 1994) Adrenarche Secondary and Tertiary Adrenal insufficiency Insulin at physiological concentrations increases Cushings disease mRNA levels of 17α-hydroxylase and type II 3βHSD Primary cortisol resistance in the absence of cAMP or ACTH in primary cul- Puberty Congenital adrenal hyperplasia tures of human adrenocortical cells (KRISTIANSEN et Ectopic ACTH Syndrome al. 1997), while insulin growth factor I (IGF-I) stim- Partial hypopituitarism Aging End-stage renal disease ulates androgen biosynthesis through the interaction with IGF-I receptor and IGF-I binding proteins in human adrenal primary cultures (FOTTNER et al. 1998). Growth hormone (GH) increases DHEAS levels adrenal gland undergoes a process of maturation, in human fetal adrenals (BROWN et al. 1978), but on with progressive broadening of the inner cortical area the other hand, AA are suppressed in patients with and creation of the zona reticularis. This is accom- GH deficiency (COHEN et al. 1981). panied by an elevation in AA concentration called Prolactin (PRL) stimulates steroidogenesis in guin- adrenarche which contributes to the development ea-pig (O CONNELL et al. 1994) and human (GLASOW of pubic and axillary hair in both sexes. Again, de- et al. 1996) adrenals in vitro. However, no correla- spite this increase in AA secretion, concentration, tions between PRL and AA levels through different excretion and average production of cortisol remain stages of life have been found (PARKER et al. 1978; costant (PARKER et al. 1978). Secretion of GnRH at HAMMOND et al. 1979). puberty activates the pituitary-gonadal axis causing Among the pituitary peptides, β-endorphin, β-li- a large increase in concentrations of testosterone and potropin and other peptides derived from pro-opi- estradiol in boys and girls respectively. During this omelanocortin (POMC) have been linked to AA reg- time, we also observe an increase in DHEA, DH- ulation. B-endorphin and β-lipotropin levels rise with EAS and ADION, which continues through the third adrenarche (GENAZZANI et al. 1983) and are high in decade of life (ADAMS 1985; PARKER 1991). Aging in polycystic ovary syndrome (ALEEM and MCINTOSH healthy people is accompanied by only little chang- 1984). Another POMC-derived peptide, the so-called es in serum cortisol or aldosterone. In sharp contrast, joining peptide has been shown to stimulate AA a mark decline in both AA secretion and excretion is secretion in vitro (PARKER et al. 1989; CLARKE et al. observed in the elderly and is commonly named 1996; ORSO et al. 1996). However, such findings have adrenopause. been contested (MELLON et al. 1991; PENHOAT et al. 1991; ROBINSON et al., 1991). Extra- and intra-adrenal regulation of adrenal More recently the corticotropin-releasing hormone androgens (CRH) has been shown to stimulate DHEA secretion from human fetal adrenals (SMITH et al. 1998) and in The mechanisms underlying AA control are still young men (IBANEZ et al. 1999). Recent evidence also object of animate debate. Without any doubt, adreno- suggests that the CRH-induced increase of adrenal corticotropin (ACTH) plays an important role in stim- steroidogenesis can be blocked by CRH type-I recep- ulating AA production. However, several instances tor antagonists, which may suggest a role for this re- of dissociation between cortisol and AA secretion ceptor in AA regulation (WILLENBERG et al. 2000). (Tab 1) suggest that besides ACTH, other factors are Some growth factors have been related to AA reg- involved in AA regulation (CUTLER et al. 1979). ulation. Epidermal growth factor (EGF) and fibro- DHEA AND ADRENOPAUSE 97 blast growth factor (FGF) stimulate growth of bo- (HEYM et al. 1994), stimulates both the release of vine adrenocortical cells in vitro (HORNSBY 1985), androstenedione and DHEA (BORNSTEIN et al. 1996; while transforming growth factor β (TGF-β) reduc- HAIDAN et al. 1998). es DHEAS by increasing mRNA accumulation of Similarly, direct cellular contacts between lym- 3βHSD and decreasing those of CYP17 (LEBRETHON phocytes and ZR cells through filopodia and gap et al. 1994; STANKOVIC et al. 1994). junctions have been recently described (WOLKERS- The existence of a specific adrenal androgens DORFER et al. 1999). Moreover, activated macroph- stimulating hormone (AASH) has been postulated ages, producing IL-1, IL-6 and TNF α have been twenty years ago. However, despite claims for the demonstrated in ZR, (BORNSTEIN and CHROUSOS 1999). isolation of such a tropic hormone (PARKER et al. This intraadrenal immune-system may play a role in 1983), the evidence for this is not so striking and the the regulation of AA secretion. IL-6 stimulates the need for the existence of a separate AASH other than release of DHEA in human adrenal primary cell cul- ACTH has been often disputed. NEVILLE and OHARE ture (PAETH et al. 1997) while TNF α has been shown (1982), for example, emphasize the lack of relevant to blunt the effects of ACTH on DHEA sulfotrans- pathophysiological syndromes AASH-related, such ferase mRNA and, with less extent, on CYP17 as AASH-secreting pituitary tumors. ANDERSON mRNA in human fetal adrenal cells (LANGLOIS et al. (1980) states that the AASH does not exist and 1998 ; PARKER et al. 1998). adrenarche is related to morphological and functional change in the ZR. According to this author, the slow Adrenal androgens and adrenopause: flush-out of reticularis blood vessels after each pulse a hypothesis of ACTH would expose the inner-zone cells to the highest cortisol levels (the cortisol they produce As mentioned earlier in this paper, AA secretion themselves plus that secreted from all the cells up- in humans increases dramatically just before puber- stream) for the longest time. Progressively, ZR cells ty, during the so-called adrenarche, reaching peak would start responding to these high cortisol levels levels in the third decade of life (ADAMS 1985; PARK- by undergoing modifications in enzymatic activities, ER 1991). Then, AA levels start falling, with values with a decrease in 3βHSD and an increase in 17,20- of 20% (men) to 30% (women) of the peak by the lyase, which would explain the increased production age of 70 to 80 and the greatest decline occurring by of AA during adrenarche. (ANDERSON 1980). Differ- the ages of 50-60, the so-called adrenopause (KRO- ently, RICH et al.
Recommended publications
  • Effect of Paternal Age on Aneuploidy Rates in First Trimester Pregnancy Loss
    Journal of Medical Genetics and Genomics Vol. 2(3), pp. 38-43, August 2010 Available online at http://www.academicjournals.org/jmgg ©2010 Academic Journals Full Length Research Paper Effect of paternal age on aneuploidy rates in first trimester pregnancy loss Vitaly A. Kushnir, Richard T. Scott and John L. Frattarelli 1Department of Obstetrics, Gynecology and Women’s Health, New Jersey Medical School, MSB E-506, 185 South Orange Avenue, Newark, NJ, 07101-1709, USA. 2Department of Obstetrics, Gynecology and Reproductive Sciences, Robert Wood Johnson Medical School UMDNJ, Division of Reproductive Endocrinology and Infertility, New Brunswick, NJ. Reproductive Medicine Associates of New Jersey, Morristown NJ, USA. Accepted 16 July, 2010 A retrospective cohort analysis of patients undergoing IVF cycles at an academic IVF center was performed to test the hypothesis that male age may influence aneuploidy rates in first trimester pregnancy losses. All patients had a first trimester pregnancy loss followed by evacuation of the pregnancy and karyotyping of the abortus. Couples undergoing anonymous donor oocyte ART cycles (n = 50) and 23 couples with female age less than 30 years undergoing autologous oocyte ART cycles were included. The oocyte age was less than 30 in both groups; thereby allowing the focus to be on the reproductive potential of the aging male. The main outcome measure was the effect of paternal age on aneuploidy rate. No increase in aneuploidy rate was noted with increasing paternal age (<40 years = 25.0%; 40-50 years = 38.8%; >50 years = 25.0%). Although there was a significant difference in the male partner age between oocyte recipients and young patients using autologous oocytes (33.7 7.6 vs.
    [Show full text]
  • The Endocrinology of Aging 329 (1989); J
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Erasmus University Digital Repository ARTICLES 37. T. Crook et al., Dev. Neuropsychol. 4, 261 (1986). 344 (1988); ibid. 281, 335 (1989); M. J. West, L. butions and advice, and W. G. M. Janssen, A. P. 38. M. S. Albert, Proc. Natl. Acad. Sci. U.S.A. 93, 13547 Slomianka, H. J. G. Gundersen, Anat. Rec. 231, 482 Leonard, and R. S. Woolley for expert technical as- (1996); iiii and M. B. Moss, in Handbook of (1991); M. J. West, Neurobiol. Aging 14, 275 (1993). sistance. Research in our laboratory was supported Biology of Aging, E. L. Schneider, J. W. Rowe, T. E. 56. We thank C. A. Barnes, C. Bouras, A. H. Gazzaley, by NIH grants AG05138 and AG06647, the Human Johnson, N. J. Holbrook, J. H. Morrison, Eds. (Aca- P. Giannakopoulos, C. V. Mobbs, E. A. Nimchinsky, Brain Project MHDA52145, the Charles A. Dana demic Press, San Diego, CA, ed. 4, 1996), pp. 217– P. R. Rapp, and J. C. Vickers for their crucial contri- Foundation, and the Brookdale Foundation. 233; R. Fama et al., Arch. Neurol. 54, 719 (1997); A. Convit et al., Neurobiol. Aging 18, 131 (1997); C. R. Jack Jr. et al., Neurology 49, 786 (1997). 39. J. W. Rowe and R. L. Kahn, Science 237, 143 (1987). 40. S. L. Vincent, A. Peters, J. Tigges, Anat. Rec. 223, The Endocrinology of Aging 329 (1989); J. Tigges, J. G. Herndon, A. Peters, Neurobiol. Aging 11, 201 (1990); J. Bachevalier et al., ibid.
    [Show full text]
  • Cognition and Steroidogenesis in the Rhesus Macaque
    Cognition and Steroidogenesis in the Rhesus Macaque Krystina G Sorwell A DISSERTATION Presented to the Department of Behavioral Neuroscience and the Oregon Health & Science University School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy November 2013 School of Medicine Oregon Health & Science University CERTIFICATE OF APPROVAL This is to certify that the PhD dissertation of Krystina Gerette Sorwell has been approved Henryk Urbanski Mentor/Advisor Steven Kohama Member Kathleen Grant Member Cynthia Bethea Member Deb Finn Member 1 For Lily 2 TABLE OF CONTENTS Acknowledgments ......................................................................................................................................................... 4 List of Figures and Tables ............................................................................................................................................. 7 List of Abbreviations ................................................................................................................................................... 10 Abstract........................................................................................................................................................................ 13 Introduction ................................................................................................................................................................. 15 Part A: Central steroidogenesis and cognition ............................................................................................................
    [Show full text]
  • Reproductive DHEA-S
    Reproductive DHEA-S Analyte Information - 1 - DHEA-S Introduction DHEA-S, DHEA sulfate or dehydroepiandrosterone sulfate, it is a metabolite of dehydroepiandrosterone (DHEA) resulting from the addition of a sulfate group. It is the sulfate form of aromatic C19 steroid with 10,13-dimethyl, 3-hydroxy group and 17-ketone. Its chemical name is 3β-hydroxy-5-androsten-17-one sulfate, its summary formula is C19H28O5S and its molecular weight (Mr) is 368.5 Da. The structural formula of DHEA-S is shown in (Fig.1). Fig.1: Structural formula of DHEA-S Other names used for DHEA-S include: Dehydroisoandrosterone sulfate, (3beta)-3- (sulfooxy), androst-5-en-17-one, 3beta-hydroxy-androst-5-en-17-one hydrogen sulfate, Prasterone sulfate and so on. As DHEA-S is very closely connected with DHEA, both hormones are mentioned together in the following text. Biosynthesis DHEA-S is the major C19 steroid and is a precursor in testosterone and estrogen biosynthesis. DHEA-S originates almost exclusively in the zona reticularis of the adrenal cortex (Fig.2). Some may be produced by the testes, none is produced by the ovaries. The adrenal gland is the sole source of this steroid in women, whereas in men the testes secrete 5% of DHEA-S and 10 – 20% of DHEA. The production of DHEA-S and DHEA is regulated by adrenocorticotropin (ACTH). Corticotropin-releasing hormone (CRH) and, to a lesser extent, arginine vasopressin (AVP) stimulate the release of adrenocorticotropin (ACTH) from the anterior pituitary gland (Fig.3). In turn, ACTH stimulates the adrenal cortex to secrete DHEA and DHEA-S, in addition to cortisol.
    [Show full text]
  • Healthy Aging
    HEALTHY AGING Presented by CONTINUING PSYCHOLOGY EDUCATION 8.4 CONTACT HOURS “The ability to prolong life is indeed within our grasp.” Marie-Francoise Schulz-Aellen (1997) Course Objective Learning Objectives The purpose of this course is to provide an Upon completion, the participant will be able to: understanding of the concept of healthy aging. 1. Discuss current biological theories regarding Major topics include current biological theories the causes of aging. of aging, physical factors, prevalent diseases 2. Explain physical factors associated with aging. and health strategies, Baltimore Longitudinal 3. Acknowledge common older adult diseases and Study of Aging, psychological factors, social their recommended preventative measures. factors, long-term care, and the nature of 4. Articulate findings from the Baltimore healthy aging. Longitudinal Study of Aging. 5. Expound upon psychological effects of aging. Accreditation 6. Understand social theories of aging, and the Provider approved by the California Board of value of social support systems. Registered Nursing, Provider # CEP 14008, for 7. Describe prevalent concerns in long-term care. 8.4 Contact Hours. 8. Discuss key characteristics which promote In accordance with the California Code of healthy aging. Regulations, Section 2540.2(b) for licensed vocational nurses and 2592.2(b) for psychiatric technicians, this course is accepted by the Board of Vocational Nursing and Psychiatric Technicians Faculty for 8.4 contact hours of continuing education Neil Eddington, Ph.D. credit. Richard Shuman, MFT Mission Statement Continuing Psychology Education provides the highest quality continuing education designed to fulfill the professional needs and interests of nurses. Resources are offered to improve professional competency, maintain knowledge of the latest advancements, and meet continuing education requirements mandated by the profession.
    [Show full text]
  • Somatopause, Weaknesses of the Therapeutic Approaches and the Cautious Optimism Based on Experimental Ageing Studies with Soy Isoflavones
    EXCLI Journal 2018;17:279-301 – ISSN 1611-2156 Received: November 06, 2017, accepted: March 10, 2018, published: March 21, 2018 Review article: SOMATOPAUSE, WEAKNESSES OF THE THERAPEUTIC APPROACHES AND THE CAUTIOUS OPTIMISM BASED ON EXPERIMENTAL AGEING STUDIES WITH SOY ISOFLAVONES Vladimir Ajdžanović1*, Svetlana Trifunović1, Dragana Miljić2, Branka Šošić-Jurjević1, Branko Filipović1, Marko Miler1, Nataša Ristić1, Milica Manojlović-Stojanoski1, Verica Milošević1 1 Department of Cytology, Institute for Biological Research “Siniša Stanković”, University of Belgrade, Belgrade, Serbia 2 Clinic for Endocrinology, Diabetes and Diseases of Metabolism, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia * Corresponding author: Vladimir Z. Ajdžanović, PhD, Department of Cytology, Institute for Biological Research “Siniša Stanković”, University of Belgrade, Despot Stefan Blvd. 142, 11060 Belgrade, Serbia, Tel: +381-11-2078-321; Fax: +381-11-2761-433, E-mail: [email protected] http://dx.doi.org/10.17179/excli2017-956 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/). ABSTRACT The pathological phenomenon of somatopause, noticeable in hypogonadal ageing subjects, is based on the growth hormone (GH) production and secretion decrease along with the fall in GH binding protein and insulin-like growth factor 1 (IGF-1) levels, causing different musculoskeletal, metabolic and mental issues. From the perspective of safety and efficacy, GH treatment is considered to be highly controversial, while some other therapeutic ap- proaches (application of IGF-1, GH secretagogues, gonadal steroids, cholinesterase-inhibitors or various combi- nations) exhibit more or less pronounced weaknesses in this respect.
    [Show full text]
  • Testosterone Deficiency in Men with Heart Failure: Pathophysiology and Its Clinical, Prognostic and Therapeutic Implications
    Kardiologia Polska 2014; 72, 5: 403–409; DOI: 10.5603/KP.a2014.0025 ISSN 0022–9032 ARTYKUŁ SPECJALNY / STATE-OF-THE-ART REVIEW Testosterone deficiency in men with heart failure: pathophysiology and its clinical, prognostic and therapeutic implications Ewa A. Jankowska1, 2, 3, Michał Tkaczyszyn1, Elżbieta Kalicińska2, 4, Waldemar Banasiak2, Piotr Ponikowski2, 4 1Laboratory for Applied Research on Cardiovascular System, Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland 2Cardiology Department, Centre for Heart Diseases, Military Hospital, Wroclaw, Poland 3Institute of Anthropology, Polish Academy of Sciences, Wroclaw, Poland 4Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland HEART FAILURE: According to the data from the European Society of Cardio­ A CARDIOGERIATRIC SYNDROME logy (ESC) HF­Pilot registry [15], annual re­hospitalisation Heart failure (HF) is a disease syndrome cha­ rate and mortality among outpatients with chronic HF has racterised by large incidence and prevalence, been estimated at 31.9% and 7.2%, respectively. Thus, new which has been estimated in the developed therapeutic approaches are needed to reverse these adverse countries at 5–10/1000 persons per year epidemiological trends. In the recent years, this search for and 1–2%, respectively [1], with a clear rise new therapies for HF has focused on pathogenetic concepts of these indices with age [2–4]. In the Bri­ related to non­cardiac disturbances and abnormalities in HF tish Hillingdon study [2], the incidence of [16, 17]. In the current research on the pathophysiology and HF among subjects aged 25–34 years was natural history of HF, attention has been paid to renal dysfunc­ only 0.02/1000 persons per year, rising to tion [18–20], hepatic dysfunction [21, 22], immune activation 11.6/1000 persons per years among subjects [23], autonomic sympathetic/parasympathetic imbalance [24], aged ≥ 85 years.
    [Show full text]
  • Adrenopause Andropause Growth Hormone Somatopause
    All “HRT” is not Alike! The Necessity and Safety of Menopause is a hormone-deficiency state with known deleterious Bioidentical Sex-Steroid Restoration consequences for quality of life and health. in Menopause Estradiol-progesterone-testosterone (EPT) replacement for menopause is medically necessary. Estradiol replacement is safe when transdermal and accompanied Henry Lindner, MD by sufficient progesterone and testosterone. Hormonerestoration.com Bioidentical EPT therapy does not have the cardiovascular or breast cancer risks seen with PremPro . This presentation is available on the CD, handout How to provide EPT therapy to menopausal women Adrenopause Not Just “Sex Hormones” DHEA DHEA-S Converted into estradiol and testosterone within tissues Estradiol, progesterone, and testosterone are required for the growth, function and maintenance of all tissues in both sexes! Maintain brain function and health—vital neurosteroids Maintain tissue health/strength: skin, hair, bone, muscle, heart Improve insulin sensitivity: belly fat, risk of diabetes Reduce blood pressure: improve endothelial function Prevent atherosclerosis: reduce risk of MI, stroke What about the loss of hormones with aging? J Clin Endocrinol Metab. 1997 Aug;82(8):2396-402 Andropause Somatopause Testosterone in Men Growth Hormone Baltimore Longitudinal Study of Aging (BLSA). Harman et al., 2001 Clinical Chemistry 48, No. 12, 2002 1 Thyropause Menopause 8000 Men Women Testosterone Progesterone 7000 average 6000 5000 pg/ml Estradiol Estradiol T Endocr Rev. 1995 HP response to low T4 (2.7-3.2g/dL) Dec;16(6):686-715 4000 25-55 pg/ml 0-20 pg/ml 120 P 100 80% 3000 80 E decline 2000 60 TSH 40 1000 20 0 Carle, Thyroid.
    [Show full text]
  • From Adrenarche to Aging of Adrenal Zona Reticularis: Precocious Female Adrenopause Onset
    ID: 20-0416 9 12 E Nunes-Souza et al. Precocious female 9:12 1212–1220 adrenopause onset RESEARCH From adrenarche to aging of adrenal zona reticularis: precocious female adrenopause onset Emanuelle Nunes-Souza1,2,3, Mônica Evelise Silveira4, Monalisa Castilho Mendes1,2,3, Seigo Nagashima5,6, Caroline Busatta Vaz de Paula5,6, Guilherme Vieira Cavalcante da Silva5,6, Giovanna Silva Barbosa5,6, Julia Belgrowicz Martins1,2, Lúcia de Noronha5,6, Luana Lenzi7, José Renato Sales Barbosa1,3, Rayssa Danilow Fachin Donin3, Juliana Ferreira de Moura8, Gislaine Custódio2,4, Cleber Machado-Souza1,2,3, Enzo Lalli9 and Bonald Cavalcante de Figueiredo1,2,3,10 1Pelé Pequeno Príncipe Research Institute, Água Verde, Curitiba, Parana, Brazil 2Faculdades Pequeno Príncipe, Rebouças, Curitiba, Parana, Brazil 3Centro de Genética Molecular e Pesquisa do Câncer em Crianças (CEGEMPAC) at Universidade Federal do Paraná, Agostinho Leão Jr., Glória, Curitiba, Parana, Brazil 4Laboratório Central de Análises Clínicas, Hospital de Clínicas, Universidade Federal do Paraná, Centro, Curitiba, Paraná, Brazil 5Serviço de Anatomia Patológica, Hospital de Clínicas, Universidade Federal do Paraná, General Carneiro, Alto da Glória, Curitiba, Parana, Brazil 6Departamento de Medicina, PUC-PR, Prado Velho, Curitiba, Parana, Brazil 7Departamento de Análises Clínicas, Universidade Federal do Paraná, Curitiba, Paraná, Brazil 8Pós Graduação em Microbiologia, Parasitologia e Patologia, Departamento de Patologia Básica – UFPR, Curitiba, Brazil 9Institut de Pharmacologie Moléculaire et Cellulaire CNRS, Sophia Antipolis, Valbonne, France 100Departamento de Saúde Coletiva, Universidade Federal do Paraná, Curitiba, Paraná, Brazil Correspondence should be addressed to B C de Figueiredo: [email protected] Abstract Objective: Adaptive changes in DHEA and sulfated-DHEA (DHEAS) production from adrenal zona reticularis (ZR) have been observed in normal and pathological conditions.
    [Show full text]
  • Reproductive DHEA
    Reproductive DHEA Analyte Information - 1 - DHEA Introduction DHEA (dehydroepiandrosterone), together with other important steroid hormones such as testosterone, DHT (dihydrotestosterone) and androstenedione, belongs to the group of androgens. Androgens are a group of C19 steroids that stimulate or control the development and maintenance of male characteristics. This includes the activity of the male sex organs and the development of secondary sex characteristics. Androgens are also precursors of all estrogens, the female sex hormones. DHEA (dehydroepiandrosterone) is the aromatic C19-steroid composed of a 10,13-dimethyl, 3-hydroxy group and 17-ketone. Its chemical name is 3β-hydroxy-5-androsten-17-one, its summary formula is C19H28O2, and its molecular weight (Mr) is 288.4 Da. The structural formulas of DHEA and related androgens are shown in Fig.1 Fig.1: Structural formulas of the most important androgens DHEA Androstenedione Testosterone Dihydrotestosterone There are more than 40 other names used for DHEA, including: (+)-Dehydroisoandrosterone; (3beta, 16alpha)-3,16-dihydroxy-androst-5-en- 17-one; 5,6-Dehydroisoandrosterone; 17-Chetovis, 17-Hormoforin, Andrestenol, Diandron, Prasterone and so on. As DHEA is very closely connected with its sulfate form DHEA-S, both hormones are mentioned together in the following text. Biosynthesis DHEA is the steroid hormone belonging to the weak androgens. DHEA and DHEA-S are the major C19 steroids produced from cholesterol by the zona reticularis of the adrenal cortex (Fig.2). DHEA is also produced in small quantities in the gonads (testis and ovary3,8,14), in adipose tissue and in the brain. From this point of view DHEA belongs to the neurosteroids22.
    [Show full text]
  • Current Approach to Menopause Menopoza Güncel Yaklaşım
    REVIEW / DERLEME Van Tıp Derg 24(3): 210-215, 2017 DOI: 10.5505/vtd.2017.54154 Current Approach to Menopause Menopoza Güncel Yaklaşım Sena Sayan and Recep Yıldızhan 1Saglik Bilimleri University, Van Training and Research Hospital, Department of Obstetrics and Gynecology, Van, Turkey 2Yuzuncu Yil University, School of Medicine, Department of Obstetrics and Gynecology, Van, Turkey ABSTRACT ÖZET With the increase in the life span, the period of Yaşam süresinin artması ile fizyolojik menopoz dönemi physiological menopause also extends. Many health de uzamıştır. Vazomotor semptomlar başta olmak üzere problems, especially vasomotor symptoms, will develop bir çok sağlık sorunu gelişecektir. Tüm bunlara karşın in the period of menopause. Therefore, the medical and geliştirilen medikal ve paramedikal yöntemler sık olarak paramedical methods developed are frequently updated. güncellenmektedir. Önceki yıllarda olduğu gibi sık reçete While not being prescribed as often as in previous years, edilmemekle beraber hormon replasman tedavisi halen bu hormone replacement therapy is currently the most semptomların giderilmesinde en önemli yöntemdir. important method for relieving these symptoms. Anahtar Kelimeler: Menopoz, vazomotor semptomlar, Key Words: Menopause, hormone replacement therapy, hormon replasman tedavisi vasomotor symptoms Introduction folliculogenesis of the yet not depleted follicles, but LH and progesterone levels do not change. In Menopause, diagnosed by the absence of bleeding this period, contraception should not be neglected for at least one year after the last menstrual (4). bleeding, negatively affects the quality of life of In the postmenopausal period following 12 women. With the prolongation of the average life months of last menstrual period, follicles that are span, especially in the developed countries, almost completely exhausted do not respond to increasing demand for quality living of the elderly increased FSH and the amount of ovarian steroid population came to the forefront.
    [Show full text]
  • The Menopause and Hormone Replacement Therapy
    Postgrad Med J: first published as 10.1136/pgmj.68.802.615 on 1 August 1992. Downloaded from Postgrad Med J (1992) 68, 615 - 623 ©D The Fellowship of Postgraduate Medicine, 1992 Reviews in Medicine The menopause and hormone replacement therapy Kay-Tee Khaw Clinical Gerontology Unit, University ofCambridge School ofClinical Medicine, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK The menopause: the background Introduction 3. The postmenopause should be defined as dating from the menopause, although it cannot be The menopause is the transition from the reproduc- determined until after a period of 12 months of tive to the non-reproductive stage of life in women spontaneous amenorrhea has been observed. and is characterized clinically by permanent cessa- Though the diagnosis of menopause is based on tion of menstruation and biologically by loss of clinical signs and symptoms, primarily amenor- ovarian function. The menopause occurs around a rhoea, and confirmed when necessary with assays mean age of50 years; virtually all women by the age for steroid hormones or gonadotrophins, the loss of 55 years or so will have experienced the ofovarian function is the essential characteristic of menopause. The changes in birth and mortality menopause. Thus, a surgical menopause occurs by copyright. rates over the last century and, in particular, the after bilateral oophorectomy with or without hys- profound decline in maternal mortality in develop- terectomy, but would not include cessation of ed countries have resulted in an average life menstruation following a simple hysterectomy. expectancy ofwomen ofabout 75 years; thus, most women will be postmenopausal for one third of Age at menopause their lifetime.
    [Show full text]